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Abstract
Previous studies demonstrated that protein kinase C- d (PKC-d) inhibition with the selective inhibitor, rottlerin, resulted in
potent downregulation of type I collagen expression and production in normal human dermal fibroblasts and abrogated
the exaggerated type I collagen production and expression in fibroblasts cultured from affected skin from patients with the
fibrosing disorder systemic sclerosis (SSc). To elucidate the mechanisms involved in the ability of PKC-d to regulate collagen
production in fibroblasts, we examined the effects of PKC-d inhibition on the transcriptome of normal and SSc human
dermal fibroblasts. Normal and SSc human dermal fibroblasts were incubated with rottlerin (5 mM), and their gene
expression was analyzed by microarrays. Pathway analysis and gene ontology analysis of differentially expressed genes in
each comparison were performed. Identification of significantly overrepresented transcriptional regulatory elements (TREs)
was performed using the Promoter Analysis and Interaction Network Toolset (PAINT) program. PKC-d activity was also
inhibited using RNA interference (siRNA) and by treating fibroblasts with a specific PKC-d inhibitory cell permeable peptide.
Differential gene expression of 20 genes was confirmed using real time PCR. PKC-d inhibition caused a profound change in
the transcriptome of normal and SSc human dermal fibroblasts in vitro. Pathway and gene ontology analysis identified
multiple cellular and organismal pathways affected by PKC-d inhibition. Furthermore, both pathway and PAINT analyses
indicated that the transcription factor NFkB played an important role in the transcriptome changes induced by PKC-d
inhibition. Multiple genes involved in the degradation of the extracellular matrix components were significantly reduced in
SSc fibroblasts and their expression was increased by PKC-d inhibition. These results indicate that isoform-specific inhibition
of PKC-d profibrotic effects may represent a novel therapeutic approach for SSc and other fibrotic diseases.
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Introduction
The family of protein kinase C (PKC) serine/threonine kinases
can be divided into three subclasses based on their distinctive
structural and functional characteristics. The three subclasses of
PKC are the conventional PKCs (cPKC; a, bI, bII, and c), the
novel PKC isoforms (nPKC; d, e, g, and h), and the atypical PKC
isoforms (aPKCs; f and i/l in human/mouse) [1–7] The cPKCs
are diacylglycerol (DAG) sensitive and Ca
2+ responsive, whereas
the nPKCs are DAG sensitive but Ca
2+ unresponsive, and the
aPKCs are insensitive to both DAG and Ca
2+.
PKC-d influences a wide variety of cellular functions, most
prominently, cellular growth and proliferation [8–9]. PKC-d also
participates in the initiation, progression and maintenance of inflamma-
tory processes inducing NFkB activation, increased levels of intracellular
adhesion molecule 1 (ICAM1), increased neutrophil adhesion, as well as,
stimulation of the expression of cellular inhibitor of apoptosis (cIAP)
protein family members and of proinflammatory mediators [10–12].
Numerous studies have shown that PKC-d modulates the
expression of collagen genes and increased PKC-d has been
associated with the development of pathologic tissue fibrosis [13–
16]. For example, increased levels of PKC-d have been reported in
dermal fibroblasts from affected skin cultured from individuals
afflicted with the fibrosing disorder systemic sclerosis or sclero-
derma (SSc) [13]. Furthermore, PKC-d activation is necessary to
mediate the stimulatory effect of Connective Tissue Growth Factor
(CTGF) in cooperation with insulin/insulin growth factor 1 (IGF1)
on collagen synthesis in SSc fibroblasts [14]. PKC-d has also been
shown to interact with components of the TGF-b signaling
pathway. Other studies have shown that TGF-b activates PKC-d
which in turn positively regulates Smad3 transcriptional activity
resulting in increased transcription of COL1A2 and fibronectin
[17,18].
Rottlerin, a derivative from Mallotus phillipinensis, the medicinal
monkey face tree of India, causes potent and highly selective
inhibition of PKC-d with an IC50 of 3–6 mM, an effect 5–10 fold
more potent than for PKC-a or PKC-b and nearly 13 to 33 fold
more potent than for PKC-e, c,o rg [19]. We previously showed
that treatment of normal and SSc fibroblasts with rottlerin caused
a potent decrease in the synthesis and production of type I and
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analyze the mechanisms responsible, we examined the effects of
PKC-d inhibition with rottlerin on the transcriptome of normal
and SSc-derived human dermal fibroblasts. These studies
identified the transcription factor NFkB as a crucial participant
in one of the most affected gene networks modulated by PKC-d,
an observation confirmed by an analysis of transcription factor
binding sites demonstrating that the binding site for NFkB occurs
at a significantly greater frequency in the differentially regulated
genes than would be predicted by chance. We also found
numerous genes that are involved in the regulation of synthesis
or in the degradation of collagen and other extracellular matrix
components to be differentially expressed in normal and SSc
fibroblasts and modulated in response to PKC-d inhibition,
confirming the previous suggestions that PKC-d plays an
important role in the pathogenesis of tissue fibrosis in SSc and
other fibrosing disorders [13].
Materials and Methods
Fibroblast cultures
Normal and SSc human dermal fibroblast cell lines were
obtained from the Scleroderma Center Tissue Bank, Thomas
Jefferson University. The SSc cell lines studied had been established
fromfull-thicknessskinbiopsiesobtained from3patientswithSScof
recent onset (,18 months from the first appearance of clinically
detectable skin induration). Cell lines obtained from 3 normal
subjects were used as normal controls. The skin biopsy specimens
from the SSc patients were obtained from the leading edge of the
lesion on the forearms. The Institutional Review Board of Thomas
Jefferson University approved the use of the tissues remaining after
the diagnostic histopathologic studies for in vitro analyses. Since only
discarded tissue was used, the IRB declared this study to be exempt
and therefore neither written nor oral consent was required.
All SSc patients satisfied the criteria for classification of SSc and
had the diffuse cutaneous clinical subset of the disease as defined by
LeRoy et al [20]. Fibroblasts were expanded as described previously
[13] from the frozen stocks and were used at passages 4–10.
Treatment of cultured dermal fibroblasts with rottlerin
Normal and SSc human dermal fibroblasts were cultured in
DMEM containing 10% FBS (Life Technologies Inc., Grand
Island, New York, USA), 1% vitamins, 2 mM glutamine,
antibiotics, and fungizone in 100 mm plates until confluent, then
preincubated for 24 h with 40 mg/ml ascorbic acid phosphate
magnesium salt n-hydrate (Sigma-Aldrich, St. Louis, MO) to
optimize collagen production. Fibroblasts were then incubated for
24 h in fresh media supplemented with 40 mg/ml ascorbic acid
and a final concentration of 5 mM rottlerin (Biomol Research
Laboratories Inc., Plymouth Meeting, PA), a concentration
previously demonstrated to induce maximal effects in human
dermal fibroblasts without causing cellular toxicity [13].
RNA Interference
Normal and SSc human dermal fibroblasts were cultured in 6
well plates until confluent. Transfection of 10 nM short interfering
RNA (siRNA) directed against PKC-d was performed using the
HiPerFect reagent (Qiagen, Valencia CA) according to the
manufacturer’s protocol. At 24 h after siRNA transfection,
fibroblasts were incubated for 24 h with 40 mg/ml ascorbic acid
phosphate magnesium salt n-hydrate (Sigma-Aldrich, St. Louis,
MO) to optimize collagen production. The siRNA target
sequences were: PKC-d - AACTCTACCGTGCCACGTTT;
Control – CCGGGACACTATATTCCAGAA.
Treatment of cultured dermal fibroblasts with a PKC-d
cell permeable peptide inhibitor
Normal and SSc human dermal fibroblasts were cultured as
previously described in 6 well plates until confluent. Cultures were
then incubated for 24 h with 10 mM of a control peptide or with
10 mM of a cell permeable inhibitory peptide specific for PKC-d
(Mimotopes Pty Ltd, Clayton Victoria, AU). Fresh media were
added and fibroblasts were then incubated for 24 h with a second
10 mM aliquot of peptide and with 40 mg/ml ascorbic acid
phosphate magnesium salt n-hydrate (Sigma-Aldrich, St. Louis,
MO) to optimize collagen production. The control peptide consists
of a dimer of the TAT protein transduction domain (PTD) [21]
and its sequence was: TAT Control – RRRQRRKKRGYC-
CYGRKKRRQRRR. The PKC-d peptide sequence is the same
described in Chen et al., and consists of the N-terminal portion of
the C2 domain (aa2-10) of PKC-d fused to the TAT peptide [22]
and its sequence was: PKD-TAT – RRRQRRKKRGYCCSFN-
SYELGSL.
Microarray analysis
Following exposure to rottlerin, DNA-free total RNA was
isolated utilizing the RNeasy micro kit (Qiagen, Valencia, CA),
according to the manufacturer’s protocol. DNase-treated total
RNA was ethanol precipitated and quantified on a NanoDrop
ND-1000 spectrophotometer and RNA quality was analyzed on
an Agilent 2100 bioanalyser (Agilent Technologies, Palo Alto,
CA). Double-stranded cDNA was synthesized using T7 Oligo dT
(Integrated DNA Technologies, Coralville, IA) and Superscript II
double-stranded cDNA Kit (Invitrogen, Carlsbad, CA). Biotiny-
lated cRNA was prepared using the BioArray High Yield RNA
Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, NY).
The labeled cRNA was fragmented by heat and ion-mediated
hydrolysis and was hybridized to the Human Genome HU133A
oligonucleotide array GeneChip (Affymetrix) which contains
,500,000 spots comprised of 22,283 different probe sets
representing 14,397 unique genes. The arrays were washed and
stained using a GeneChip Fluidic Station 450 (Affymetrix), and
hybridization signals were amplified utilizing antibody amplifica-
tion with goat IgG (Sigma-Aldrich, Saint Louis, MO) and anti-
streptavidin biotinylated antibody (Vector Laboratories, Burlin-
game, CA) and then were scanned using an Affymetrix GeneChip
Scanner 3000, using GeneChip Operating Software (GCOS)
version 3.0. Background correction and normalization were done
using a Robust Multichip Average (RMA) with Genespring V 10.0
software (Agilent Technologies, Santa Clara, CA). Volcano plots
were used to identify differentially expressed genes using the
parametric testing assuming equal variances (based on the results
of a Student’s two-sample t-test for two groups).
Four different comparisons were performed: normal untreated
fibroblasts versus normal fibroblasts treated with rottlerin, SSc
untreated fibroblasts versus rottlerin treated SSc fibroblasts,
normal untreated fibroblasts versus SSc untreated fibroblasts,
and normal fibroblasts treated with rottlerin versus rottlerin
treated SSc fibroblasts. The list of differentially expressed genes for
each comparison was loaded into Ingenuity Pathway Analysis
(IPA) 5.0 software (www.ingenuity.com) to perform biological
network and functional analyses.
Transcriptional regulatory network analysis
Promoter analysis was performed using the Promoter Analysis
and Interaction Network Toolset (PAINT) v3.9 which contains a
database of promoter sequences (UpstreamDB) constructed for all
known and putative annotated genes in the Ensembl genome
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Unigene build #213 [23,24]. This encompasses 32,559 promoter
sequences in the Ensembl database cross-referenced to 19,423
promoter sequences in the Unigene database. Promoter analysis
for putative transcriptional regulatory elements (TREs) which
serve as binding sites for known transcription factors was
performed employing the MATCH algorithm which scores
potential matches based on the degree of similarity of a putative
binding site to known binding sites using known binding site
sequences contained in the TRANSFAC public database version
6.0. This analysis allows for the identification of common
upstream transcription factor binding sequences in a list of genes
and compares the prevalence of sequences within the set to that
expected to be found by chance in a given list of TREs. PAINT
analysis is a function of upstream sequence information and is
independent of gene expression levels.
Each group of genes from the microarray analysis categories
was tested for significantly overrepresented TREs against the
entire set of genes in the Human Genome U133 Plus 2.0 array,
which represent the global set of TREs affected by the
experimental conditions. The default settings of the parameters
of the program were utilized in the analysis. Statistical significance
for TRE overrepresentation was set at p,0.05 with additional
filtering performed by setting the false discovery rate (FDR) at 0.3.
Identification of statistically significant enrichment of a specific
TRE within a particular expression cluster indicates a role for the
cognate transcription factor in the coordinate regulation of genes
in that cluster.
Validation of microarray results utilizing RT-PCR
A selected subset of differentially expressed genes was chosen for
independent verification by SYBR Green-based, real-time RT-
PCR (Applied Biosystems, Foster City, CA) following a standard
amplification protocol on an ABI Prism 7900 Sequence Detection
System (Applied Biosystems) using b-actin as an internal reference
standard. Primer pairs (Integrated DNA Technologies, Coralville,
IA) for representative genes from the analyzed data are listed in
Table S1. Relative quantification was assessed by arbitrarily
setting the expression level of the saline negative control at 100
and by expressing changes in transcript levels of other samples
relative to this control sample. Relative differences in each PCR
sample were corrected using human b-actin mRNA as an
endogenous control. Real-time PCR values reflect the mean and
standard deviation of triplicate samples. The statistical significance
of the real-time PCR data was assessed by Student’s two-tailed t
test. P values less than 0.05 were considered significant.
Accession Numbers
The entire dataset discussed in this paper is compliant to the
Minimum Information About a Microarray Experiment (MIAME)
criteria and has been deposited at Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE23741)
under accession number GSE23741 (platform ID: GPL570; dataset
IDs: GSM585874-GSM585885).
Results
Global gene expression of cultured normal and SSc
dermal fibroblasts induced by PKC-d inhibition
Transcriptome profiling was performed employing microarray
analysis on total RNA isolated from untreated and rottlerin-
exposed human dermal fibroblasts derived from normal skin
biopsies or from biopsies of affected skin from patients with diffuse
SSc. Following normalization of hybridization intensities using the
RMA (Robust Multichip Array) algorithm in the Genespring 7.3.1
software, the average expression level for each gene was calculated
from biological duplicates. The values were plotted in a Volcano
plot analyzing expression patterns in untreated normal fibroblasts
versus rottlerin treated normal fibroblasts in Figure 1a and in
untreated SSc fibroblasts versus rottlerin treated SSc fibroblasts in
Figure 1b using the –log10[p-value] and –log2[fold change].
These assessments allowed filtering of the differentially expressed
genes at a particular p-value. In order to discover specific patterns
hierarchical clustering (Pearson correlation) was applied to the
expression profiles of the total group of differentially expressed
transcripts (Figure 2). A summary of the number of differentially
expressed transcripts is depicted in Table 1.
Exposure of normal and SSc fibroblasts to rottlerin induced
changes of 2 fold or greater in the expression level of a total of 433
gene transcripts at a significance level of p,0.05, of which 320
were upregulated and 113 were downregulated. The upregulation
of nearly 3 times more genes than those that are downregulated
indicate that PKC-d functions primarily as a transcriptional
repressor in human dermal fibroblasts. Interestingly, the response
of the transcriptome to rottlerin exposure differed dramatically
depending upon the origin of the dermal fibroblasts. Of the
differentially regulated transcripts, the expression levels of a total
of 147 (128 upregulated and 19 downregulated) were changed in
both normal and SSc cultured dermal fibroblasts. However, a total
of 192 transcripts (117 upregulated and 75 downregulated) were
expressed differentially only in fibroblasts derived from normal
donors whereas expression levels changed for a total of 95
transcripts (75 upregulated and 20 downregulated) only in
fibroblasts derived from SSc donors. A partial list of the most
upregulated transcripts is displayed in Table 2 and a partial list of
the most downregulated transcripts is displayed in Table 3.
Biological network and functional analysis of transcripts
differentially regulated by rottlerin
To analyze the functional effects of the transcripts differentially
regulated by rottlerin the entirety of differentially expressed
transcripts in each comparison (normal untreated vs. normal
rottlerin treated, and untreated SSc vs. rottlerin treated SSc) was
loaded into the pathway analysis program in order to generate
network, functional, and pathway analyses. The pathway analysis
converted the lists of Affymetrix ID for transcripts with
accompanying expression level information into a set of relevant
networks based on the Ingenuity Pathways Knowledge Base
(IPKB). The transcripts were categorized based upon molecular
function in the IPA software and the identified transcripts were
also mapped to genetic networks in the IPA database and ranked
by score. This score reflects the probability that a collection of
genes equal to or greater than the number in a particular network
could be achieved by chance alone. A score of greater than 25 was
used as a cutoff for identifying gene networks. The network with
the highest score for the normal untreated control vs. normal
rottlerin treated comparison is composed of 32 differentially
regulated genes and is depicted in Figure 3a. The network with
the highest score for the untreated SSc versus the rottlerin treated
SSc comparison is composed of 29 differentially regulated genes
and is depicted in Figure 3b. The networks for each comparison
share 19 genes in common with each other, whereas the network
generated in the untreated normal versus the rottlerin treated
comparison contains 13 unique genes and the network generated
in the untreated SSc versus the rottlerin treated SSc comparison
contains 10 unique genes. Interestingly, the transcription factor
NFkB appears as a central molecule in both networks even though
its transcription levels are not directly affected. The list of networks
PKC-d Inhibition Modifies Fibroblast Transcriptome
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27110Figure 1. Volcano plot of differentially expressed transcripts. (A) Normal untreated vs normal rottlerin-treated fibroblasts. (B) SSc untreated
vs SSc rottlerin-treated fibroblasts. A volcano plot of genes differentially expressed in human dermal fibroblasts exposed to rottlerin. The X-axis
represents the log
2 values of the fold change observed for each transcript whereas the Y axis depicts the log
10 values of the p value of the
significance tests between replicates for each transcript. Genes that demonstrate a 2 fold or greater difference in expression at a p value,0.05 in
rottlerin treated cells compared to untreated cells are displayed in red. Dots representing genes of interest validated by RT-PCR are labeled.
doi:10.1371/journal.pone.0027110.g001
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comparison is displayed in Table 4 and the list of networks
generated for the comparison between untreated SSc and rottlerin
treated SSc is displayed in Table 5.
The functional pathway analysis demonstrated that PKC-d
inhibition affected the transcriptional levels of genes from diverse
pathways that are involved in a variety of pathological conditions,
such as: cancer, inflammatory, gastrointestinal, reproductive,
cardiovascular and hematological diseases. As reported in
numerous studies, PKC-d inhibition differentially regulated genes
involved in diverse cellular functions including cell death, cell cycle
control, growth and differentiation, amino acid metabolism, small
molecule biosynthesis, cell to cell signaling and interaction, as well
as, cellular movement [8–12]. Numerous genes involved in
Figure 2. Heat map and dendrogram of differentially expressed transcripts. GeneSpring analysis of normal and SSc human dermal
fibroblasts exposed to rottlerin. RNA was isolated from replicate samples of normal human dermal fibroblasts incubated under control conditions
(NC) or cultured with 5 mM rottlerin (NR), or from SSc derived human dermal fibroblasts under control conditions (SC) or cultured with 5 mM rottlerin
(SR), labeled and applied to Affymetrix human U133 2.0 Plus microarrays. Dendrograms are reflective of the genes with a differential expression of .2
fold in the two experimental conditions. In the dendrogram shown, a shorter arm indicates higher similarity, whereas a longer arm indicates lower
similarity. Genes with significant expression (p,0.05) between untreated and rottlerin treated fibroblasts were hierarchically clustered by similarity in
expression profile. The resulting heat map of the dendrogram tree reveals groups of genes with high (red) expression levels, low expression levels
(blue) or background expression levels (yellow).
doi:10.1371/journal.pone.0027110.g002
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regulated.
Targeting of PKC-d activity using RNA interference and a
PKC-d inhibitory cell-permeable peptide
Although nanomolar concentrations of rottlerin potently inhibit
PKC-d activity, at higher concentratiions rottlerin can also
suppress the activity of other kinases [25] and can also uncouple
mitochondrial respiration from oxidative phosphorylation. To
ensure that the observed effect of rottlerin on the transcriptome is
due to its inhibition of PKC-d and is not the result of possible
effects on other protein kinases or caused by rottlerin-induced
mitochondrial uncoupling, PKCd activity was also targeted in
fibroblasts via RNA interference and the use of a specific cell
permeable PKC-d inhibitory peptide. Normal and SSc fibroblasts
were transfected with control and PKC-d specific siRNA or were
cultured in media containing either a control peptide consisting of
a dimer of the TAT protein transduction domain (PTD) [21] or
with a PKC-d specific inhibitory peptide that targets the N-
terminal C2 domain fused to a single TAT PTD [22]. The C2
domain of PKC isoenzymes is a region within the regulatory
domain that mediates protein-protein interactions between
individual PKC isozymes and their achoring proteins, receptors
for activated C kinase (RACKs). The PKC-d -specific peptide
binds to the specific RACKs, preventing PKC-d binding, thereby
disrupting the anchoring and functioning of PKC-d [26]. RNA
from these experiments was utilized in validation of gene
expression regulated by PKC-d inhibition. The effects of rottlerin,
of RNA interference and of peptide-mediated PKC-d inhibition
on the expression of PKC-d in normal and SSc fibroblasts were
evaluated by real time RT-PCR. The PKC-d specific siRNA
induced an 84% decrease in PKC-d mRNA levels in normal
fibroblasts and an 88% decrease in SSc cells (data not shown). The
control siRNA had no appreciable effect on PKC-d expression
compared to the saline control. As expected, the PKC-d inhibitory
peptide did not induce a change in PKC-d mRNA levels in either
normal or SSc fibroblasts.
Validation of genes differentially expressed in response
to PKC-d inhibition by real time RT-PCR
The relative expression levels of selected highly expressed genes
and of genes from the two most significant networks obtained in
the IPA analysis were confirmed by real time RT-PCR performed
on RNA isolated from each of three sources: rottlerin-treated
fibroblasts, siRNA-treated fibroblasts or peptide-treated fibro-
blasts. The successful validation of a total of 12 genes is displayed
in Figures 4 and 5. Seven genes that were downregulated in
response to rottlerin were selected for validation. These were:
chromosome 5 open reading frame 13 (c5orf13), chemokine CXC
motif ligand 6 (CXCL6), chemokine CXCL12, interferon-
inducible guanylate binding protein 1 (GBP1), receptor interacting
serine/threonine kinase 4 (RIPK4), also known as PKC-d
interacting protein kinase (DIK) or ankyrin repeat domain-
containing protein kinase 3 (ANKRD3); SRY-box 9 (SOX9) and
tumor necrosis factor receptor superfamily, member 19
(TNFRSF19). Figure 4a displays the real time RT-PCR
expression levels for these 7 downregulated genes in rottlerin
treated fibroblasts, whereas Figure 4b displays expression levels
for the same set of genes in siRNA-treated fibroblasts and
Figure 4c shows the expression of these genes in fibroblasts
treated with the PKC-d inhibitory peptide. The control siRNA
and the control peptide did not affect the expression levels of these
genes compared to the saline control. All genes examined
demonstrated the same consistent pattern of decreased expression
in response to PKC-d inhibition that was observed in the
microarray analysis.
Six genes that were upregulated in response to PKC-d
inhibition were also chosen for validation. These were, DNA
damage inducible transcript 3/C/EBP homologous protein
(DDIT3/CHOP), DNA damage inducible transcript 4/Regulated
in development and DNA damage responses 1 (DDIT4/REDD1),
growth/differentiation factor 15 (GDF15), pentraxin 3 (PTX3)
thrombomodulin (THBD), and tribbles homolog 3 (TRIB3).
Figure 5a displays the real time RT-PCR expression levels for
these 6 upregulated genes in rottlerin treated fibroblasts, whereas
Table 1. Number of differentially expressed transcripts in control fibroblasts vs rottlerin exposed human dermal fibroblasts
derived from normal or SSc patients at different statistical criteria using Volcano plot as a filter.
Upregulated Downregulated Total
Transcripts Differentially Regulated by Rottlerin, 2 Fold, p,0.05
Untreated vs Rottlerin 320 113 433
Common Rottlerin Responsive 128 19 242
Rottlerin Responsive in Normal Cells Only 117 74 191
Rottlerin Responsive in SSc Cells Only 75 20 95
Transcripts Differentially Regulated in SSc Fibroblasts, 2 Fold, p,0.05
Normal vs SSc 34 41 75
Common in Untreated and Rottlerin-treated Cells 10 5 15
Differentially Expressed in Untreated 10 18 28
Differentially Expressed in Rottlerin-treated 14 18 32
Transcripts Differentially Regulated in SSc Fibroblasts, 1.5 Fold, p,0.10
Normal vs SSc 191 169 360
Common in Untreated and Rottlerin-treated Cells 38 23 61
Differentially Expressed in Untreated 62 72 134
Differentially Expressed in Rottlerin-treated 91 74 165
doi:10.1371/journal.pone.0027110.t001
PKC-d Inhibition Modifies Fibroblast Transcriptome
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27110Figure 5b displays expression levels for the same set of genes in
siRNA-treated fibroblasts and Figure 5c shows the expression of
these genes in fibroblasts treated with the PKC-d inhibitory
peptide. The control siRNA and the control peptide did not affect
the expression levels of these genes compared to the saline control.
All genes examined displayed changes in expression in cells in
which PKC- d was inhibited by each of three methods consistent
with those observed in the microarray analysis.
Genes differentially regulated in SSc-derived dermal
fibroblasts
A similar analysis of differentially expressed transcripts between
untreated normal fibroblasts versus untreated SSc-derived fibro-
blasts (normal control vs. SSc control) and between rottlerin
treated normal fibroblasts versus rottlerin treated SSc-derived
fibroblasts (normal rottlerin vs. SSc rottlerin) yielded a total of 75
genes that displayed a 2 fold or greater difference in expression at
a p-value of p,0.05 (Table 1). Since SSc is a complex disorder
Table 2. Selected upregulated rottlerin responsive
transcripts.
Gene Symbol Description Fold
Change
Transcripts Upregulated by Rottlerin in Normal and SSc cells
GDF15 growth differentiation factor 15 24.9
TRIB3 tribbles homolog 3 (Drosophila) 12.4
DDIT4 DNA-damage-inducible transcript 4 9.6
ASNS asparagine synthetase 8.4
SLC7A11 solute carrier family 7 member 11 8.1
SLC7A5 solute carrier family 7 member 5 7.3
TRIB3 tribbles homolog 3 (Drosophila) 7.0
SLC7A11 solute carrier family 7, member 11 6.5
PSAT1 phosphoserine aminotransferase 1 6.2
CTH cystathionase (cystathionine gamma-lyase) 6.0
SLC22A15 solute carrier family 22, member 15 5.7
PSAT1 phosphoserine aminotransferase 1 5.7
Transcripts Upregulated by Rottlerin in Normal Cells Only
IL8 Interleukin 8 6.0
ITGB3 integrin, beta 3 4.4
SLC38A1 solute carrier family 38, member 1 4.4
CBS cystathionine-beta-synthase 4.3
RRAGD Ras-related GTP binding D 4.2
CD55 CD55 molecule 4.2
AKR1C1 Aldo-keto reductase family 1, member C1 3.8
PION pigeon homolog (Drosophila) 3.6
VEGFA vascular endothelial growth factor A 3.4
SLC4A7 solute carrier family 4, member 7 3.4
BEX4 brain expressed, X-linked 4 3.3
Transcripts Upregulated by Rottlerin in SSc Cells Only
THBD Thrombomodulin 5.1
THBD Thrombomodulin 5.0
SLC6A15 solute carrier family 6 member 15 4.4
THBD Thrombomodulin 4.2
PTGS1 prostaglandin-endoperoxide synthase 1 3.6
IGDCC4 Ig superfamily, DCC subclass, member 4 3.3
JARID2 jumonji, AT rich interactive domain 2 3.1
GADD45A growth arrest and DNA-damage-induc., 45a 2.9
PTGS2 prostaglandin-endoperoxide synthase 2 2.9
IL20RB Interleukin 20 receptor beta 2.9
NAMPT nicotinamide phosphoribosyltransferase 2.8
Fold change indicates the difference between untreated normal or SSc cells
compared to rottlerin treated normal or SSc cells. The entire dataset discussed
in this paper is deposited at Gene Expression Omnibus (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE23741) under accession number GSE23741.
doi:10.1371/journal.pone.0027110.t002
Table 3. Selected downregulated rottlerin responsive
transcripts.
Gene Symbol Description Fold Change
Transcripts Downregulated by Rottlerin in Normal and SSc cells
C5orf13 24.4
SOX9 SRY (sex determining region Y)-box 9 24.3
SOX9 SRY (sex determining region Y)-box 9 23.8
GBP1 Guanylate binding protein 1, IFN-inducible 23.0
GBP1 Guanylate binding protein 1, IFN-inducible 22.9
C5orf13 chromosome 5 open reading frame 13 22.6
CXCL12 chemokine (C-X-C motif) ligand 12 22.5
CARHSP1 calcium regulated heat stable protein 1 22.5
HUNK hormonally up-reg. Neu-associated kinase 22.4
METTL7A methyltransferase like 7A 22.4
TNFRSF19 TNF receptor superfamily, member 19 22.4
HELLS helicase, lymphoid-specific 22.4
Transcripts Downregulated by Rottlerin in Normal Cells Only
FAM65B family w/sequence similarity 65, memb.B 23.5
SHROOM3 shroom family member 3 23.2
23.1
ST6GALNAC5 Alpha-2,6 sialyltransferase 23.1
PSRC1 proline/serine-rich coiled-coil 1 23.1
SOCS2 suppressor of cytokine signaling 2 23.0
MYLIP myosin reg. light chain interacting protein 23.0
MRVI1 murine retrovirus integ. site 1 homolog 22.8
GNG2 guanine nucleotide binding protein, c 2 22.8
MKI67 antigen identified by MAb Ki-67 22.8
C5orf13 chromosome 5 open reading frame 13 22.7
Transcripts Downregulated by Rottlerin in SSc Cells Only
CXCL6 chemokine (C-X-C motif) ligand 6 23.5
CLIC3 chloride intracellular channel 3 23.3
PHACTR3 phosphatase and actin regulator 3 23.1
DIRAS3 DIRAS family, GTP-binding RAS-like 3 23.1
FN1 fibronectin 1 22.6
MCM4 minichromosome maintenance complex 4 22.6
TEAD2 TEA domain family member 2 22.4
OLFML1 olfactomedin-like 1 22.4
MCM5 minichromosome maintenance complex 5 22.3
GINS4 GINS complex subunit 4 (Sld5 homolog) 22.3
RAB7B RAB7B, member RAS oncogene family 22.2
Fold change indicates the difference between untreated normal or SSc cells
compared to rottlerin treated normal or SSc cells. The entire dataset discussed
in this paper is deposited at Gene Expression Omnibus (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE23741) under accession number GSE23741.
doi:10.1371/journal.pone.0027110.t003
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27110Figure 3. Functionally related gene networks constructed from the (A) normal untreated vs normal rottlerin-treated comparison or
(B) SSc untreated vs SSc rottlerin-treated comparison. Differentially expressed genes for each comparison were entered into Ingenuity
Pathwork Analysis (IPA) software v 5.0. Nodes represent genes, with their shape representative of the functional classification of the gene product as
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27110Table 4. Selected genetic networks with high scores (.26) in Normal Control vs Normal Rottlerin-exposed human dermal
fibroblasts.
Molecules in Network Score Focus Genes Top Functions
ASNSq, ATF4q, BEX2q, CEBPGq,C T H q, DDIT4q, EIF2AK3q, GARSq,
GBP2Q, GBP1 Q, GDF15q, HERPUD1q, IFN-cq, IFNGR1q, IFRD1q,
LY96q, MFHAS1q, MT1Eq, MTHFD2q, MTSS1q, NCOA7q, NFkB (comp),
PCK2q, PDGF BB, PSAT1q, PSPHq, PTX3q, RND3q, RRN3q,
SHMT2q, TNFRSF19Q, TRIB3q, TXNRD1q, WARSq, XPOTq
64 32 Amino acid metabolism; small molecule
biochemistry; carbohydrate metabolism
AKT, APC, BIRC5Q, C1ORF103q, C5ORF13Q, Caspase, CDC20Q,
CDCA8Q, Cyclin A, Cyclin E, DHFRQ, E2f, FGF2q, GPNMBq,
Hdac, Histone h3, Histone h4, HMMRQ,
Hsp27Q, Hsp70q, HSPB1Q, MCM5Q, MKI67Q, MT1Fq,
MT1Gq, MXD1q, NUPR1q, NUSAP1Q, PTGS1q, Rb, Rsk,
TGIF1q, TPX2Q, TYMSQ, VEGFAq
37 22 Cell cycle; cardiovascular system
development
and function; organismal development
CARHSP1Q, CENPE, CHMP2B, COG5 (includes EG:10466) q, DSN1, ELK3,
ERBB2, GTSE1Q, HSPA9q,J M Y q, Jmy-p300q,
KIAA0101Q, MIS12, MKI67Q, MXD3Q, NBR1, NCAPD2, NCAPG
(includes EG:64151) Q, NCAPH, NDC80Q, NUF2Q, POLG,
POLHQ,P S R C 1 Q, PXN, RPSA, SH2D5q, SLC19A2q, SPC24, SPC25Q,
SQSTM1q, TACC3Q, TP53, TTC5, ZWINT (includes EG:11130) Q
29 19 Cell cycle; cellular assembly and organization;
DNA replication, recombination and repair
ABCG8, ACOX1, ACSL1, ARG2, BAAT, BNC1q, CDCA2Q, DNMT3L, EXO1Q, FABP2,
FAM65BQ, GPT2q, HDAC1, HNF4A, HUNKQ, MDH1, MOCOSq, NAGA, NDUFA1,
NDUFV1, NRBF2q, NUCB1, PCK2q, PPP1CA, PSMA3, RSL24D1q, RXRA, SESN2q,
SLC2A4, SLC38A1q, SLMO2q, SYTL2Q, TCF19Q, TUBE1q, UHRF1BP1q
26 17 Lipid metabolism; small molecule
biochemistry; cardiovascular disease
ASB1q, BCAT1q, C9ORF72q, CARSq, CDCA3Q, CIDEC, EAF2q, EPRSq, GARSq,
HSP90AA1, IARSq, IKBKG, Integrin alpha V beta 3q, KCNG1q, KDM5B, MARSq,
NCAPH, NDRG4Q, NET1, NFIL3, NOD2, PA2G4, PIRq, PPAP2B, progesterone,
PTGER4, RYR3, SAA1, SLC39A14q, SMYD3q, SRXN1q, TGFB1, TMEM14AQ,
TNFSF11, ZFP36
26 17 Cellular growth and proliferation; embryonic
development; reproductive system function
and development
doi:10.1371/journal.pone.0027110.t004
depicted in the inset box. All of the upregulated genes are displayed in red whereas all of the downregulated genes are displayed in green and the
degree of differential expression is reflected by the intensity of the color, with darker colors indicating a greater level of differential expression.
doi:10.1371/journal.pone.0027110.g003
Table 5. Selected genetic networks with high scores (.26) in SSc Control vs SSc Rottlerin-exposed human dermal fibroblasts.
Molecules in Network Score
Focus
Genes Top Functions
ARG2q, ASNSq, BEX2q, CEBPGq, CHMP2Bq,C T H q,
CXCL6Q, DDIT4q, DUSP6q, EIF2AK3q, GBP1 (includes
EG:2633) Q, GDF15q, Hdac, HERPUD1q, Ifn gamma, IFRD1q,
LY96q, MT1Eq, MTHFD2q, MTSS1q, MXD1q, NCOA7q,N F k B
(complex), PCK2q, PDGF BB, PHLDA1q, PSAT1q, RIPK4Q, SLC1A1q,
SQSTM1q, THBDq, Tlr, TNFRSF19Q, TRIB3q, VitaminD3-VDR-RXR
59 29 Amino acid metabolism; small
molecule biochemistry; genetic disease
CBSq, DBP, DCK, ELL, GAS1Q, GDF15q, GINS2Q, GINS4Q, GSTM4,
HDAC8, HNF4A, HSPH1, HUNKQ,J M Y q, Jmy-p300q, KLHL24q, MIR124,
MOCOSq, NAMPTq, NBR1, RCHY1, RMND1, RSL24D1q, SEL1L, SESN2q,
SLC17A5q, SLC31A1q, SLC38A1q, SNAI2, TEAD2Q, TP53,
TRIP11, TTC5, TUBE1q, UBQLN2
32 19 Cell-to-cell signaling and interaction; cellular
function and maintenance; infection mechanism
Collagen(s), CXCL12Q, Elastase, ERK, Fibrin, Fibrinogen, FN1Q, Focal
adhesion kinase, GFPT1q, HOMER1q, ICAM1q, IL8q, Integrin,
Integrin alpha 3 beta 1, LDL, LRP, Mek, MKNK2q, NAMPTq,
NfkB1-RelA, NPC1q, NRP2q, Pak, Pdgf, PLAURq, Rac, Rap1, RCAN1q,
SLC3A2q, SLC7A5q, SLC7A11q, THBS1Q, Vegfq, VEGFAq,V L D L R q
29 18 Cellular assembly and organization; cellular
function and maintenance; protein trafficking
Ap1, ARL4Cq, ASF1BQ, ATP2B1q, Creb, Cyclin A, DNAJB9q, E2f, EPORq,
ERK1/2, FSH, G alphai, GAS1Q, GOT1q, hCG, Histone h3, Histone h4, IL12
(complex), JARID2q, Lh, Mapk, MCM4Q, MCM5Q, MCM10Q, MT1Fq, MT1Xq,
PFKFB2q, Pka, Pkc(s), PLC, PLC gamma, Pldq, PP2A, STX3q, UHRF1Q
26 16 Hematological system development and function;
hematopoiesis; tissue morphology
Akt, C1ORF103q, Caspase, CLIP1q, Cyclooxygenaseq, EIF4EBP1q,
FTH1q, G-protein beta, GADD45Aq, GNA13q, Gpcr, HMOX1q, Hsp27Q,
Hsp70q,H S P A 5 q, HSPA9q, HSPB3Q, IFN Beta, IKK (complex), IL1,
Insulin, Interferon alpha, Jnk, MHC Class II, NUPR1q, P38 MAPK, PI3K,
PTGS1q, PTGS2q, Ras, Ras homologQ, RORAq, Sapk, TGIF1q, WARSq
26 16 Cardiovascular system development and function;
connective tissue disorders; drug metabolism
doi:10.1371/journal.pone.0027110.t005
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variability in expression patterns, the criteria for analysis were
broadened to include transcripts displaying a 1.5 fold or greater
change in expression level with a p-value of 0.10. This resulted in
the identification of a total of 360 differentially expressed genes
(191 upregulated and 169 downregulated) between normal versus
SSc-derived fibroblasts irrespective of whether or not the cells had
been treated with rottlerin (Table 1). Of these 360 genes, 61 genes
were differentially expressed (38 upregulated and 23 downregu-
lated) in both the untreated and rottlerin-treated SSc fibroblasts
compared to their normal counterparts. Untreated fibroblasts
demonstrated 134 transcripts (62 upregulated and 72 downregu-
lated) that were differentially regulated in SSc-derived fibroblasts
compared to normal-derived fibroblasts, whereas rottlerin treated
SSc-derived fibroblasts displayed 165 unique transcripts (91
upregulated and 74 downregulated) that were differentially
regulated compared to normal-derived fibroblasts. A partial list
of the most upregulated transcripts in SSc fibroblasts is displayed
in Table 6 and a partial list of the most downregulated transcripts
in SSc fibroblasts is displayed in Table 7.
Several genes known to be involved in the regulation of
production and maintenance of the extracellular matrix (ECM) or
Figure 4. Validation of expression levels of downregulated genes following PKC-d inhibition. A. mRNA expression levels of 7
downregulated genes in normal and SSc human dermal fibroblasts following treatment with A. 5 mM rottlerin, B. 10 nM PKC-d siRNA, C. 10 mM cell
permeable specific PKC-d inhibitory peptide for 24 h. Results are expressed as mean percent difference +/2 SD of 3 replicate samples analyzed by
quantitative RT-PCR. The PBS control was arbitrarily set to 100% expression. NC: Normal untreated fibroblasts, NR: Normal treated fibroblasts, SC: SSc
untreated fibroblasts, SR: SSc treated fibroblasts. Statistical significance was calculated to compare treated vs untreated normal or SSc fibroblasts.
*: p,0.1; **: p,0.01; ***: p,0.0001.
doi:10.1371/journal.pone.0027110.g004
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insulin growth factor binding protein 7 (IGFBP7), plasminogen
activator urokinase (PLAU), Wnt-inducible signaling protein 2
(WISP2), were upregulated in SSc-derived dermal fibroblasts
compared to normal dermal fibroblasts. The expression patterns of
transcripts for these genes in control and PKC- d-inhibited normal
and SSc fibroblasts, as well as for those encoding type I and type
III collagen were examined by real time RT-PCR. Figure 6a
displays expression levels in rottlerin treated normal and SSc
fibroblasts whereas Figure 6b displays expression levels in siRNA
treated fibroblasts and Figure 6c displays expression of these
genes in fibroblasts treated with the inhibitory PKC-d peptide.
The control siRNA and the control peptide did not affect the
expression levels of these genes compared to the saline control.
Expression of these genes as measured by real time PCR was
consistent with the pattern observed in the microarray results.
Microarray results indicated that cyclooxgenase 1/prostaglan-
din synthase 1 (COX1/PTGS1) and cyclooxygenase 2/prosta-
Figure 5. Validation of expression levels of upregulated genes following PKC-d inhibition. A. mRNA expression levels of 6 upregulated
genes in normal and SSc human dermal fibroblasts following treatment with A. 5 mM rottlerin, B. 10 nM PKC-d siRNA, C. 10 mM cell permeable
specific PKC-d inhibitory peptide for 24 h. Results are expressed as mean percent difference +/2 SD of 3 replicate samples analyzed by quantitative
RT-PCR. The PBS control was arbitrarily set to 100% expression. NC: Normal untreated fibroblasts, NR: Normal treated fibroblasts, SC: SSc untreated
fibroblasts, SR: SSc treated fibroblasts. Statistical significance was calculated to compare treated vs untreated normal or SSc fibroblasts. *: p,0.1;
**: p,0.01; ***: p,0.0001.
doi:10.1371/journal.pone.0027110.g005
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PLoS ONE | www.plosone.org 11 November 2011 | Volume 6 | Issue 11 | e27110glandin synthase 2 (COX2/PTGS2), important mediators of
arachidonic acid and prostaglandin synthesis were strongly
downregulated in untreated SSc-derived fibroblasts compared to
normal untreated fibroblasts as were matrix metalloproteinase 3
(MMP3), pentraxin-3 (PTX3) and suppressor of cytokine signaling
2 (SOCS2). Rottlerin strongly induced upregulated expression
COX1/PTGS1, MMP3 and PTX3 but upregulated expression of
COX2/PTGS2 was observed only in rottlerin-treated SSc
fibroblasts and upregulated SocS2 expression only in rottlerin-
treated normal fibroblasts The expression patterns of transcripts
for these genes in control and PKC- d-inhibited normal and SSc
fibroblasts, as well as for those encoding type I and type III
collagen were examined by real time RT-PCR. Figure 7a
displays expression levels in rottlerin treated normal and SSc-
derived fibroblasts whereas Figure 7b displays expression levels in
siRNA treated fibroblasts and Figure 7c displays expression of
these genes in fibroblasts treated with the inhibitory PKC- d
peptide. The control siRNA and the control peptide did not affect
the expression levels of these genes compared to the saline control.
COX1a/PTGS1a, COX1b/PTGS1b, COX2/PTGS2, MMP3,
PTX3 and SOCS2 were downregulated in untreated SSc
fibroblasts versus untreated normal fibroblasts (Figure 7a–c).
PKC-d inhibition strongly induced expression of COX1a/
PTGS1a, COX1b/PTGS1b, MMP3 and PTX3 in both normal
and SSc fibroblasts whereas COX2/PTGS2 expression was
induced only in treated SSc fibroblasts and SocS2 expression
was induced only in treated normal fibroblasts. This expression
pattern was consistent with the pattern observed in the microarray
Table 6. Selected transcripts upregulated in SSc fibroblasts.
Gene Symbol Description Fold Change
Transcripts Upregulated in SSc vs NormalFibroblasts
IGFBP5 insulin-like growth factor binding protein 5 5.0
FGFR2 fibroblast growth factor receptor 2 4.6
POMZP3 POM and ZP3 fusion zona pellucida glycoprotein 3 4.5
FGFR2 fibroblast growth factor receptor 2 4.4
FGFR2 fibroblast growth factor receptor 2 4.3
POMZP3 POM and ZP3 fusion zona pellucida glycoprotein 3 4.1
CADP5 Ca++-dependent secretion activator 5 3.9
NFIB nuclear factor I/B 3.8
MCAM melanoma cell adhesion molecule 3.3
MRVI1 murine retrovirus integration site 1 3.2
Transcripts Upregulated in Untreated SSc vs Untreated Normal FibroblastsCells Only
ACTG2 actin, gamma 2, smooth muscle, enteric 6.0
ITGA7 integrin, alpha 7 4.4
ANK2 ankyrin 2, neuronal 4.4
CLIC3 chloride intracellular channel 3 4.3
EBF1 early B cell factor 1 4.3
ANK2 ankyrin 2, neuronal 4.2
CDO1 cysteine dioxygenase 1 4.2
HSPB7 heat shock 27 kDa protein family, member 7 3.8
AFF3 AF4/FMR2 family, member 3 3.6
CAMK2D calcium/calmodulin-dependent protein kinase II delta 3.4
CD74 CD74 molecule, MHC, class II invariant chain 3.4
Transcripts Upregulated in SSc Rottlerin-Treated vs Normal Rottlerin-Treated Fibroblasts Cells Only
DES desmin 5.6
PRUNE2 prune homolog 2 (Drosophila) 5.3
CSGALNA chondroitin sulfate Nacetylgalactosaminyltransferase 1 5.2
ACTC1 actin, alpha, cardiac muscle 1 5.0
TM4SF20 transmembrane 4 L six family member 20 3.8
PLAU plasminogen activator, urokinase 3.7
FHL1 four and a half LIM domains 1 3.6
FOS v-fos FBJ murine osteosarcoma viral oncogene 3.6
FHL1 four and a half LIM domains 1 3.3
FHL1 four and a half LIM domains 1 3.2
MEF2C myocyte enhancer factor 2C 3.1
Fold change indicates the difference between untreated or treated normal cells compared to untreated or treated SSc cells. The entire dataset discussed in this paper is
deposited at Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE23741) under accession number GSE23741.
doi:10.1371/journal.pone.0027110.t006
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siRNA or PKC- d-inhibitory peptide increased the expression
levels of COX1 isoforms 1 and 2, COX2, MMP3 and PTX3
(Figure 7a–c). Expression of type I and type III collagen were
also upregulated in SSc-derived fibroblasts compared to normal
fibroblasts by real time RT-PCR although this upregulation was
not observed in the microarray results, possibly due to the very
high fibroblast expression levels of these genes.
To further confirm the validity of the results, the production of
type I collagen by the cultured fibroblasts and the effect of rottlerin
on type I collagen production by these cells was evaluated by
Western blots of culture supernatants. Consistent with previously
described results, SSc-derived dermal fibroblasts showed substan-
tially increased levels of type I collagen production compared to
normal dermal fibroblasts. Exposure to rottlerin induced a
dramatic reduction in type I collagen production in both normal
and SSc-derived dermal fibroblasts (data not shown).
Analysis of common transcription regulatory networks
Analysis of the promoter regions of the 443 genes differentially
regulated in response to rottlerin was performed by entering the
transcript IDs into the PAINT program. The analysis revealed a
statistically significant association between the presence of specific
TREs and exposure to rottlerin. The results of promoter analysis
filtered by p,0.05 with the FDR set at ,0.3 demonstrated 14
Table 7. Selected transcripts downregulated in SSc fibroblasts.
Gene Symbol Description Fold Change
Transcripts Downregulated in SSc vs NormalFibroblasts
CDH2 cadherin 2, type 1, neuronal 5.0
B3GACTL beta 1,3-galactosyltransferase-like 4.6
GRIK2 glutamate receptor, ionotropic, kainate 2 4.5
SSTR1 somatostatin receptor 1 4.4
DACT1 dapper, antagonist of beta-catenin, homolog 1 4.3
CDH2 cadherin 2, type 1, neuronal 4.1
TSPAN13 tetraspanin 13 3.9
SIPR1 sphingosine-1-phosphate receptor 1 3.8
TBX3 T-box 3 3.3
NID2 nidogen 2 (osteonidogen) 3.2
COL13A1 collagen, type XIII, alpha 1 2.9
Transcripts Downregulated in Untreated SSc vs Untreated Normal FibroblastsCells Only
DAB1 disabled homolog 1 (Drosophila) 6.0
PTGS1 prostaglandin-endoperoxide synthase 2 4.4
TMTC2 transmembrane and tetratricopeptide repeat cont. 2 4.4
RUNX3 runt-related transcription factor 3 4.3
PID1 phosphotyrosine interaction domain containing 1 4.3
SOCS2 suppressor of cytokine signaling 2 4.2
CRISPLD2 cysteine-rich secretory protein LCCL domain cont. 2 4.2
IFI27 interferon, alpha-inducible protein 27 3.8
CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2) 3.6
DSEL dermatan sulfate epimerase-like 3.4
NDRG4 NDRG family member 4 3.4
Transcripts Downregulated in SSc Rottlerin-Treated vs Normal Rottlerin-Treated Fibroblasts Cells Only
LHX8 LIM homeobox 8 8.2
MMP3 matrix metallopeptidase 3 (stromelysin 1) 5.3
C9orf167 chromosome 9 open reading frame 167 3.6
AKR1C1 Aldo-keto reductase family 1, member C1 3.5
C9orf167 chromosome 9 open reading frame 167 3.0
CALB2 calbindin 2 2.8
FOXF1 forkhead box F1 2.7
DOK6 docking protein 6 2.6
DIO2 deiodinase, iodothyronine, type II 2.6
MALAT1 metastasis assoc. lung adenocarcinoma trans. 1 2.5
FAM44A family with sequence similarity 44, member A 2.4
Fold change indicates the difference between untreated or treated normal cells compared to untreated or treated SSc cells. The entire dataset discussed in this paper is
deposited at Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE23741) under accession number GSE23741.
doi:10.1371/journal.pone.0027110.t007
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response to rottlerin. These factors were: transcription factor CP2
(TFCP2), olfactory neuronyl transcription factor 1/early B-cell
factor 1 (OLF1/EBF1), aryl hydrocarbon receptor nuclear
translocator/hypoxia inducible factor 1 (ARNT/HIF1), myogenin
(MYOG), NFkB, E2F, selenocysteine tRNA gene transcription
activating factor (STAF), hepatocyte nuclear factor 4 (HNF4),
paired box gene 6 (PAX6), CCAAT box binding protein,
cooperates with myogenic protein 1 (COMP1), upstream stimu-
latory factor (USF), v-ets avian erythroblastosis virus E26
oncogene homolog 1(c-ETS1) and E26-like protein 1 (ELK1) as
shown in Table S2. The identification of statistically significant
enrichment of a specific TRE within a particular expression cluster
may indicate a role for the cognate transcription factor in
coordinate regulation of genes in that cluster. An analysis of the
359 transcripts differentially regulated between normal and SSc-
derived dermal fibroblasts identified 4 transcription factors TREs
that were enriched in response to rottlerin. These factors were
upstream transcription factor 1 (USF1), STAT1, cAMP response
element binding protein (CREB) and cJun (Table S2).
Discussion
PKC-d has been implicated as a regulator of a wide variety of
cellular processes and has been shown to participate in the
pathogenesis of numerous disorders. PKC-d also plays an
important role in tissue fibrosis as it is regulated by TGF-b.
TGF-b activates PKC-d which in turn positively regulates Smad3
transcriptional activity, resulting in increased transcription of
genes encoding various collagens and fibronectin [17,18]. Other
studies have shown that production and secretion of type I
collagen by vascular smooth muscle cells requires PKC-d [15].
Figure 6. Validation of expression levels of genes upregulated in SSc fibroblasts compared to normal fibroblasts following PKC-d
inhibition. mRNA expression levels of 7 upregulated genes in normal and SSc human dermal fibroblasts following treatment with A. 5 mM rottlerin,
B. 10 nM PKC-d siRNA, C. 10 mM cell permeable specific PKC-d inhibitory peptide for 24 h. Results are expressed as mean percent difference +/2 SD
of 3 replicate samples analyzed by quantitative RT-PCR. The PBS control was arbitrarily set to 100% expression. NC: Normal untreated fibroblasts, NR:
Normal treated fibroblasts, SC: SSc untreated fibroblasts, SR: SSc treated fibroblasts. Statistical significance was calculated to compare treated vs
untreated normal or SSc fibroblasts. *: p,0.1; **: p,0.01; ***: p,0.0001.
doi:10.1371/journal.pone.0027110.g006
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stimulatory effect of CTGF in cooperation with insulin/insulin
growth factor 1 (IGF1) on collagen synthesis in SSc fibroblasts [14].
In a previous study we demonstrated that SSc fibroblasts have
substantially increased levels of PKC-d compared to normal
fibroblasts and that exposure of these fibroblasts to rottlerin
resulted in a .80% reduction in COL1A1 mRNA, and a .70%
reduction in COL3A1 mRNA with a corresponding decrease in
the production of these proteins. The role of PKC-d in the
regulation of collagen gene expression was further documented by
the demonstration that a dominant-negative form of PKC-d
caused a potent decrease in the transcription of the type I collagen
gene promoter [13].
Given the demonstrated effect of rottlerin to downregulate the
production of type1 and type 3 collagens, we undertook the
present study in order to gain a better understanding of the effects
of rottlerin on the transcriptome of fibroblasts to identify molecules
and pathways that may be important in the pathogenesis of
fibrotic diseases such as SSc. Microarray analysis on total RNA
isolated from rottlerin-treated and non-treated normal and SSc
fibroblasts yielded a total number of 433 gene transcripts that
displayed a greater than 2 fold difference in expression at a
significance level of p,0.05 (Table 1, Figure 1). Since
experimental replicates were not used in this study, transcripts
displaying a fold change of less than 2 fold were excluded. The
differentially regulated genes are involved in many of the processes
already attributed to be regulated by PKC-d activity. These
include: cell death, cell cycle control, cell growth and proliferation,
cellular movement, cell-cell interaction, amino acid synthesis and
tumor morphology as well as embryonic, tissue, hematopoietic and
Figure 7. Validation of expression levels of genes downregulated in SSc fibroblasts compared to normal fibroblasts following PKC-
d inhibition. mRNA expression levels of 6 downregulated genes in normal and SSc human dermal fibroblasts following treatment with A. 5 mM
rottlerin, B. 10 nM PKC-d siRNA, C. 10 mM cell permeable specific PKC-d inhibitory peptide for 24 h. Results are expressed as mean percent difference
+/2 SD of 3 replicate samples analyzed by quantitative RT-PCR. The PBS control was arbitrarily set to 100% expression. NC: Normal untreated
fibroblasts, NR: Normal treated fibroblasts, SC: SSc untreated fibroblasts, SR: SSc treated fibroblasts. Statistical significance was calculated to compare
treated vs untreated normal or SSc fibroblasts. *: p,0.1; **: p,0.01; ***: p,0.0001.
doi:10.1371/journal.pone.0027110.g007
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associated with the development of a variety of disease conditions,
such as: cancer, gastrointestinal, reproduction, cardiovascular and
hematological diseases as well as various genetic disorders. The
gene network displaying the greatest number of genes that were
differentially regulated showed that one of the central molecular
hubs was the NFkB transcription factor. The important role of
NFkB was an observation strongly supported by the PAINT
analysis of the TREs that are enriched at a significantly greater
level than chance in untreated versus rottlerin treated fibroblasts
which identified the NFkB TRE.
Although several recent papers have shown that rottlerin is a
potent PKC-d inhibitor exerting its effects on PKC-d at
nanomolar concentrations, it has become apparent that at much
higher concentrations it can also inhibit other kinases [25].
Rottlerin can also uncouple mitochondrial respiration from
oxidative phosphorylation and some of the effects on apoptosis
previously attributed to PKC-d could be caused by mitochondrial
uncoupling and increased ROS production. However, the results
we obtained did not provide compelling evidence of a role in
mitochondrial uncoupling in dermal fibroblasts, one of the effects
attributed to rottlerin, although, on the contrary, three genes
encoding proteins located in the mitochondria [27–29] were
upregulated in response to rottlerin, namely, mitochondrial
phosphoenolpyruvate carboxypeptidase 2 (PCK2), mitochondrial
serine hydroxymethyltransferase 2 (SHMT2), and mitochondrial
lon peptidase 1 (LONP1). Among these only LONP1 has been
reported to be affected by mitochondrial uncoupling [29].
Additionally, in order to address the possibility that the microarray
results reflected changes in the transcriptome mediated by targets
of rottlerin other than PKC-d, we also isolated and analyzed RNA
from normal and SSc fibroblasts in which PKC-d activity had
been targeted by RNA interference or with a cell-permeable PKC-
d inhibitory peptide. The real time PCR results from these PKC-d
inhibited fibroblasts support the conclusion that the differential
expression observed in the microarray data can be attributed to
inhibition of PKC-d activity by rottlerin.
Twelve genes that were part of the most differentially regulated
networks (Figure 3) or that were among the most strongly
differentially expressed genes identified in our microarray analysis
were randomnly selected for verification by real time PCR.
Changes in the expression levels of these genes were analyzed and
confirmed using RNA from fibroblasts in which PKC-d activity
was targeted by exposure to rottlerin, exposure to PKC-d
inhibitory peptide or by RNA interferenece. The upregulated
genes that were confirmed (Figure 5) were: DDIT3/CHOP, a
dominant negative inhibitor of C/EBP and CCAAT/enhancer
binding protein beta [30]; DDIT4/REDD1, a transcriptional
target of p53 which is upregulated by hypoxia [31]; GDF15, also
known as macrophage inhibitory cytokine 1 (MIC1) which is
expressed in activated but not in resting macrophages [32];
THBD, an endothelial cell surface protein which forms a complex
with thrombin and coverts it into a physiologic anticoagulant [33]
and TRIB3, a negative regulator of the transcription factors AKT,
NFkB, AP1 and oncogenic ras [34]. It was of interest that among
the genes found to be downregulated by inhibition of PKC-d
activity there were several genes that are likely to participate in the
development of fibrotic reactions. Thus, these genes represent
novel or less well recognized participants in the fibrotic process
that were upregulated by PKC-d. The profibrogenic genes that
were downregulated by PKC-d inhibition (Figure 4), which were
confirmed by RT-PCR, included c5orf13, which downregulates
TGF-b1 and TGF-bR2 and has been shown to decrease collagen
expression and induce differentiation of myofibroblasts to
fibroblasts [35]; CXCL6, a chemokine that displays increased
expression during progression of liver fibrosis [36]; CXCL12, a
chemokine that is a powerful attractant for fibrocytes and that
participates in the angiogenesis associated with chronic inflam-
mation and fibrosis and has been found to be increased in
pulmonary fibrosis tissues [37–39]; GBP1, an interferon inducible
guanylate binding protein that is expressed at gap junctions and is
involved in endothelial cell proliferation and invasion [40]; SOX9,
which is coexpressed with Col2a1, the gene encoding type II
collagen, the major cartilage matrix protein [41] and which has
recently been suggested to participate in SSc fibrosis [42]; and
TNFRSF19, which is expressed primarily in prostate cells and is
capable of activating the JNK pathway and of inducing NFkB
activation [43].
Analysis of the differential expression of genes between normal
and SSc fibroblasts identified a total of 75 genes that displayed a
greater than 2 fold difference in expression with a p value , 0.05.
However, to make the results of our studies comparable to other
previously published studies comparing the normal and SSc
transcriptomes [44–47], we reanalyzed the data including genes
with differential expression greater than 1.5 fold and a significance
of p,0.10 to reflect the high level of heterogeneity known to exist
even between fibroblasts derived from normal and SSc skin
biopsies. Using these parameters, we identified 360 genes that
were differentially expressed between normal and SSc fibroblasts.
Interestingly, only 61 of these transcripts were unaffected by
rottlerin treatment. However, 134 transcripts were differentially
expressed only in untreated cells, while 165 transcripts were
differentially expressed only in rottlerin treated cells.
Urokinase plasminogen activator (PLAU), which has been
implicated as a suppressor of fibrosis via activation of MMPs [48]
was upregulated in normal fibroblasts but not in SSc fibroblasts
following PKC-d inhibition (Figure 6). Expression of COX1a,
COX1b, and COX2 which regulate prostaglandin synthesis
thereby suppressing the synthesis of collagen [49,50]; and SOCS2,
which acts to suppress insulin growth factor 1 (IGF1) and growth
hormone (GH) mediated deposition of excessive collagen [51]
were significantly downregulated in untreated SSc cells (Figure 7).
Treatment with rottlerin, PKC-d specific siRNA or with a PKC-d
inhibitory peptide dramatically induced expression of COX1a,
COX1b, COX2 and SOCS2, an effect which would be expected
to abrogate some of the potent PKC-d profibrotic effects.
Furthermore, MMP3, a matrix metalloproteinase involved in
collagen remodeling [52] and PTX3, a gene involved in innate
immune responses that is found to be elevated in the serum of SSc
patients and that is constitutively expressed in SSc fibroblasts
[53,54] were downregulated in SSc fibroblasts following inhibition
of PKC-d activity (Figure 7).
The general pattern observed for genes involved in tissue
fibrosis is that those genes which act to induce fibrosis and
stimulate collagen and ECM production were suppressed in
fibroblasts exposed to rottlerin whereas those genes normally
associated with the suppression of fibrosis, inhibition of collagen
production or increased collagen degradation were upregulated in
response to rottlerin treatment. These results indicate that the
potent inhibitory effect of rottlerin treatment on collagen
production that we previously reported is not due solely to a
decrease in transcription of the type I collagen genes but, instead,
it appears to be the result of an inhibitory effect on multiple genes
involved in the upregulation of expression of profibrotic molecules
and a stimulatory effect on genes encoding collagenolytic and
other antifibrotic molecules. These observations, therefore,
indicate a much broader participation of PKC-d in the
pathogenesis of tissue fibrosis and suggest that inhibition of the
PKC-d Inhibition Modifies Fibroblast Transcriptome
PLoS ONE | www.plosone.org 16 November 2011 | Volume 6 | Issue 11 | e27110broad spectrum of its profibrogenic effects may be a novel and
effective therapeutic approach for SSc and other fibrosing diseases.
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